In a significant development for tobacco regulation, the U.S. Food and Drug Administration (FDA) has issued modified risk orders for 20 ZYN nicotine pouch products, allowing them to be marketed with a specific claim: using ZYN instead of cigarettes puts adults at lower risk of certain diseases. This decision comes as new data shows youth tobacco use in the United States has fallen to historically low levels, highlighting a potential shift in the public health landscape.
The FDA's action, based on scientific review, authorizes ZYN nicotine pouches to carry the claim that using them instead of cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. Importantly, the FDA did not declare these products safe, nor did it encourage non-smokers to start using them. The authorization is intended to help adults who smoke understand the relative risks and make informed choices.
This move underscores a critical distinction between combustible cigarettes and smoke-free nicotine alternatives. While nicotine products are addictive and not risk-free, they are not equivalent to the harms of smoking. For adults who would otherwise continue smoking, access to accurate information about scientifically substantiated alternatives is crucial, according to Dr. Matthew Holman, vice president and chief science and regulatory strategy officer for PMI U.S., the company behind ZYN.
The timing is notable given the latest data on youth tobacco use. According to the FDA's analysis of the 2025 National Youth Tobacco Survey, current use of tobacco products, including combustible products and e-cigarettes, declined between 2022 and 2025. Nicotine pouch use among youth remained low and stable, with 1.7 percent of students reporting current use in 2025, compared with 1.8 percent in 2024. These figures suggest that the progress in reducing youth tobacco use is not compromised by the availability of FDA-authorized alternatives for adults.
For business and technology leaders, this development carries significant implications. The FDA's decision sets a precedent for how smoke-free nicotine products can be marketed, potentially opening new opportunities for companies in the tobacco and nicotine sector. It also signals a regulatory environment that recognizes harm reduction, which could influence future product innovations and market strategies.
However, the authorization comes with responsibilities. PMI U.S. has implemented responsible marketing practices, including advertising only with individuals aged 35 or older, age verification on websites, and restrictions on social media. The company has also outlined a 10-point approach to underage prevention, which includes retail support programs, monitoring of underage-use data, and support for FDA enforcement.
The public health community has long struggled with balancing preventing youth initiation and providing alternatives for adult smokers. The new data and FDA action suggest these goals can coexist. As Dr. Holman notes, the United States has made extraordinary progress in reducing youth tobacco use, and the next step is to bring the same seriousness to helping adults who smoke transition to better alternatives.
This policy shift could have a global impact, as other countries look to the U.S. for guidance on tobacco regulation. The FDA's evidence-based approach may encourage similar frameworks internationally, potentially reshaping the global tobacco market. For now, the focus remains on protecting youth while offering adult smokers a path to reduced risk.
